Sabby Management’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-261
Closed -$2.85M 114
2020
Q3
$2.85M Buy
+261
New +$29K 0.43% 34
2019
Q1
Sell
-743
Closed -$5.64M 88
2018
Q4
$5.64M Sell
743
-1,172
-61% -$91.5K 1.24% 13
2018
Q3
$15.2M Buy
1,915
+549
+40% +$41.5K 1.94% 13
2018
Q2
$9.59M Sell
1,366
-5,957
-81% -$429K 1.48% 17
2018
Q1
$51.2M Sell
7,323
-150
-2% -$10.4K 6.09% 2
2017
Q4
$51.9M Buy
7,473
+5,228
+233% +$353K 4.72% 7
2017
Q3
$15.2M Sell
2,245
-9,966
-82% -$630K 0.99% 18
2017
Q2
$83.3M Buy
12,211
+4,874
+66% +$318K 5.45% 4
2017
Q1
$45.7M Buy
+7,337
New +$427K 2.46% 11
2016
Q4
Sell
-1,760
Closed -$11.6M 301
2016
Q3
$11.6M Buy
+1,760
New +$115K 0.43% 40
2015
Q1
Sell
-2,503
Closed -$17.6K 295
2014
Q4
$17.6K Buy
2,503
+1,000
+67% +$71.6K 0.56% 25
2014
Q3
$18.9K Buy
1,503
+351
+30% +$25.7K 0.72% 25
2014
Q2
$8.56M Buy
+1,152
New +$83.3K 0.37% 41
2013
Q4
Sell
-241
Closed -$1.25M 221
2013
Q3
$1.25M Sell
241
-4,588
-95% -$230K 0.08% 111
2013
Q2
$22.8M Buy
+4,829
New +$246K 1.52% 17

Other funds holding AZN

Sabby Management's AZN Position: Q1 2021 in Review

Sabby Management sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 182,500 shares — an estimated $18.2M sold.

Sabby Management first reported a position in AZN in Q3 2013 and held it in 8 quarters. The position peaked at $18.2M in Q4 2020. 756 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

  • Sabby Management reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
  • Sabby Management sold 182,500 AstraZeneca shares in Q1 2021, an estimated $18.2M.
  • Sabby Management first reported a position in AstraZeneca in Q3 2013 and held it in 8 quarters.
  • Sabby Management's AstraZeneca position peaked at $18.2M in Q4 2020.
  • 756 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.